非转移性NSCLC国际多学科共识:弥合证据与实践
该国际共识采用改良Delphi流程,由89名胸部肿瘤专家对96条预设临床声明进行评分,共识阈值定为至少75%的评分在7-9分。最终62条(64%)达成共识,31条(32%)未达成共识,3条(3%)被拒绝。共识支持常规FDG PET-CT分期、纵隔淋巴结组织学确认、反射性PD-L1检测和DNA-based NGS、标准化新辅助后病理评估,以及选择性的周围型≤2cm淋巴结阴性肿瘤行亚肺叶切除加系统淋巴结评估;不可切除II-III期同步放化疗后度伐利尤单抗巩固治疗不论PD-L1表达均获支持。
要点
- 共识支持非转移性NSCLC诊断时常规行FDG PET-CT分期及纵隔淋巴结组织学确认。
- 支持诊断时反射性PD-L1检测和DNA-based NGS,以及标准化新辅助后病理评估。
- 选择性的周围型≤2cm淋巴结阴性肿瘤可行亚肺叶切除加系统淋巴结评估。
核心结论
- 该国际共识为非转移性NSCLC实践中的不确定领域提供了结构化专家指导,并强调了未来前瞻性研究的优先方向。
研究设计与样本
- 采用改良Delphi流程,于2025年9月3-5日在西班牙巴塞罗那举行为期3天的面对面会议。
- 共89名胸部肿瘤专家对工作组制定并经指导委员会完善的预设临床声明进行独立评分。
- 采用9点Likert量表评估同意程度,共识预设为至少75%的评分在7-9分范围,拒绝预设为至少75%的评分在1-3分范围。
主要发现
- 共评估96条声明,其中62条(64%)达成共识,31条(32%)未达成共识,3条(3%)被拒绝。
- 共识支持常规FDG PET-CT分期、纵隔可疑淋巴结组织学确认、诊断时反射性PD-L1检测和DNA-based NGS、标准化新辅助后病理评估。
- 共识支持选择性的周围型淋巴结阴性肿瘤(≤2cm)行亚肺叶切除加系统淋巴结评估。
- 不可切除II-III期疾病同步放化疗后度伐利尤单抗巩固治疗获支持,不论PD-L1表达。
- 持续争议领域包括I期疾病脑MRI、诱导治疗后纵隔再分期、常规RNA-based检测以及循环肿瘤DNA或MRD指导围手术期决策。
关键数值与推荐
- 共识阈值:至少75%的评分在7-9分范围;拒绝阈值:至少75%的评分在1-3分范围。
- 96条声明中62条(64%)达成共识,31条(32%)未达成共识,3条(3%)被拒绝。
- 支持亚肺叶切除加系统淋巴结评估的条件为选择性的周围型淋巴结阴性肿瘤且≤2cm。
- 支持度伐利尤单抗巩固治疗的条件为不可切除II-III期疾病同步放化疗后,不论PD-L1表达。
临床怎么用
- 非转移性NSCLC诊断时应常规行FDG PET-CT分期并对纵隔可疑淋巴结行组织学确认。
- 诊断时应行反射性PD-L1检测和DNA-based NGS,新辅助治疗后应行标准化病理评估。
- 选择性的周围型≤2cm淋巴结阴性肿瘤可行亚肺叶切除加系统淋巴结评估。
- 不可切除II-III期患者同步放化疗后可行度伐利尤单抗巩固治疗,不论PD-L1表达。
局限性
- I期疾病脑MRI、诱导治疗后纵隔再分期、常规RNA-based检测及ctDNA/MRD指导围手术期决策等领域未达成共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The management of non-metastatic NSCLC has become increasingly complex with the integration of multimodality strategies and biomarker-driven approaches. Several clinically relevant areas remain insufficiently defined by current evidence and international guidelines. We conducted an international multidisciplinary consensus to address major areas of uncertainty in real-world practice. METHODS: A modified Delphi process was conducted during a 3-day in-person meeting in Barcelona, Spain (September 3-5, 2025). A total of 89 thoracic oncology experts independently rated predefined clinical statements developed by working groups and refined by a steering committee. Agreement was assessed using a 9-point Likert scale. Consensus was predefined as more than or equal to 75% of ratings in the 7 to 9 range; rejection was predefined as more than or equal to 75% in the 1 to 3 range. RESULTS: A total of 96 statements were evaluated. Consensus was achieved for 62 statements (64%), 31 (32%) remained without consensus, and three (3%) were rejected. Consensus supported routine 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography for staging, histologic confirmation of suspicious mediastinal nodes, reflex programmed death-ligand 1 testing and DNA-based next-generation sequencing at diagnosis, standardized post-neoadjuvant pathologic assessment, and sublobar resection with systematic nodal evaluation for selected peripheral node-negative tumors less than or equal to 2 cm. Consolidation durvalumab after definitive chemoradiotherapy was supported irrespective of programmed death-ligand 1 expression in unresectable stages II to III disease. Persistent areas of controversy included brain magnetic resonance imaging in stage I disease, mediastinal restaging after induction therapy, routine RNA-based testing, and the use of circulating tumor DNA or minimal residual disease to guide perioperative decisions. CONCLUSIONS: This international consensus provides structured expert guidance in areas of uncertainty in non-metastatic NSCLC and highlights priorities for future prospective research.
引用
- Meyer ML, Peters S, Borghaei H, et al. Bridging Evidence and Practice: International Multidisciplinary Consensus on Non-Metastatic NSCLC. J Thorac Oncol. 2026. PMID: 42532338. doi:10.1016/j.jtho.2026.104111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。